How Clinical Trials Have Intersected with My Practice of Clinical Medicine

,

Written by: Chand Khanna, DVM, PhD, DACVIM (Onc), DACVP (Hon)

My history.

It was never intended, but innovation and clinical trials have always been part of my practice of veterinary oncology. I have spent the bulk of my professional life as a practicing veterinary oncologist and actively offering clinical trial options to my patients and clients. I am the founder of The Oncology Service LLC, which is a group of specialty veterinary oncology practices in the greater Washington DC area, recently acquired by Ethos Veterinary Health (where I now continue to seek and develop innovations for our patients, as its Chief Science Officer and President of Ethos Discovery, in the form of novel therapeutics and diagnostics developed through clinical trials). In my practice of veterinary oncology I was always on the search for new options to deliver on the unmet needs of my patients. The additional option of therapeutics only available through clinical trials has been a key feature of my practice of clinical medicine and has delivered many favorable intended and unintended consequences.

For my patients and clients.

As is the case for human cancer patients, there are times when conventional treatment options do not deliver on a patient’s/family’s goals, risks, or pragmatic needs (i.e. cost/insurance, treatment time/location), and in such instances I have found it most valuable for my clients to consider clinical trial options. Through these trials they may be better able to align their perspectives on goals, risks, and pragmatic needs with more available options than may be the case through a conventional treatment path, alone. In addition, this includes the opportunity to receive state-of-the-art and cutting-edge therapy often before any other cancer patients.

For my practice of medicine.

An obvious and expected consequence of offering clinical trials to my patients is the proximity that I have been given to the cutting edge of innovation and the feeling that I am extending my work beyond the simple delivery of historical standards. This has been highly rewarding to me personally and genuinely appreciated by my clients, and is largely responsible for my ability to stay integrated and active in clinical practice despite many distractions and other responsibilities. While drafting this document an unintended consequence of this proximity to innovation recently became apparent to me. This unintended consequence has been a distinct and clearer understanding of the shortcomings of our conventional approaches to deliver medicine to patients. This understanding is not always shared by my colleagues who have not been as motivated by innovation.

For our business.

Both during my leadership of my own practices and within my current responsibilities at Ethos, the opportunity to conduct clinical trials has created a valuable differentiation to allure innovation-minded doctors and staff and immediately deliver this differentiation to pet owners interested in state-of-the-art care.

It is not always easy.

For many reasons, delivering care through clinical trials is not simple, easy, or efficient. The repetition of conventional medicine allows efficiency and workflows that can be tailored to the needs and perspectives of a specific staff. This efficiency is immediately disrupted by the rigor, evidence, and structure of a clinical trial. In short, this creates change, and with change comes short-term pain.

Not all clinical trials are the same.

In the veterinary field, not all clinical trials are the same, and not all clinical trials come with the same levels of pain or disruption. A simple distinction of trials includes whether the trial is conducted under regulatory oversight (i.e. FDA) or whether the trial is simply a research study. Regulatory studies often result in additional demands of hospital teams and doctors and creates greater changes in existing workflows. This distinction is not absolute since there are some regulatory studies that can be conducted without as much demands, and there are research studies that can be highly intensive and disruptive. Different clinical groups can experience these pains in different ways, and experience has taught me what types of trials are most burdensome to my practice of medicine, and for the most part, I can now avoid these trial designs.

How to overcome the pain.

It often seems intuitively obvious that more money and more support will alleviate the pains associated with a clinical trial. In many different situations I found this not to be the case. Indeed, I have found that the most effective and productive way to overcome the challenges of a clinical trial is by starting with a high level of doctor and hospital curiosity in the medicine or the innovation of a trial. When such curiosity and interest is high, teams will find ways to “roll with the punches” and deliver both high accrual and high quality data to studies. When such curiosity or interest is not high, there is likely no amount of external support that can solve or even fully understand the challenges of a trial.

Our approach at Ethos.

Through Ethos, much of our scientific innovation is delivered through a standalone not-for-profit incubator of scientific innovation called Ethos Discovery (501c3; www. ethosdiscovery.org). Ethos Discovery begins its cycle of innovation by understanding the unmet therapeutic and diagnostic needs articulated by its staff to begin the process of innovation. Once understood and characterized, these needs are aligned with scientific partners around the world who may be best positioned to deliver innovation to the identified need. This results in questions that should be at the top of the list of curiosity and interest for our Ethos doctors and staff, but also at the highest level of need for our clients and patients. Accordingly, we should have an intrinsic method to manage the pains of clinical trials. Nonetheless, we are aware of the need and value of help to staff in the launch and management of trials across multiple geographically distinct practices and now have dedicated and trained staff to support our clinical trial aspirations. However, the curiosity and interest of clinical teams motivated by innovation and seeking more for their patients remains a paramount differentiator of our approach. It is therefore essential that our teams see the work of Ethos Discovery to be theirs and for Ethos Discovery to be their 501c3.

Ethos Discovery Receives Support from Frankie’s Friends

,

Woburn, Mass. — March 11, 2020: Ethos Discovery is excited to announce a $12,000 donation received by Frankie’s Friends in support of the Ethos Discovery’s Hemagiosarcoma and Sepsis research programs. This contribution will help Ethos Discovery continue its work to improve health outcomes for animals and humans with complex medical problems.

“Frankie’s Friends is a nonprofit organization dedicated to finding cures and saving pets with life-threatening conditions. We are pleased to further the incredible research being conducted ethically and humanely by Ethos Discovery, in hopes of providing a better quality of life for pets in need of emergency and specialty veterinary care. Frankie’s Friends provides financial assistance for pets in need of emergency and specialty veterinary care whose families cannot afford the full cost of the treatments needed to save their lives. For more information, please visit www.frankiesfriends.org.”

Ethos Discovery is a 501(c)(3) nonprofit that internally develops and answers its own clinical research questions. We are agnostic to the source of good ideas and uniquely positioned, with the support of Ethos Veterinary Health, to reach patients and doctors nationally and partner with key leaders in their field internationally. Ethos Discovery pursues impactful research that will make a difference where it is most important, at the point of care and to patients and families in the community and beyond. Our work is funded through philanthropic donations from like-minded individuals and organizations like Frankie’s Friends.

 

 

Vuja De Sciences Announces the Appointment of Two New Board Members

,

New members bring unparalleled scientific and clinical expertise to anti-metastasis approaches in osteosarcoma and cancer in general, for both human and veterinary settings.

HOBOKEN, N.J. (PRWEB) January 07, 2020 – Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to its Board of Directors. Rick Lampe, Co-founder and CEO of Vuja De said, “We are delighted to welcome Chand and Lee as new directors. They will be of great help in advancing our unique approach to the discovery and development of metastatic progression targeting cancer treatments in osteosarcoma and other cancers.” Dr. David Warshawsky, Vuja De’s Founder and Chairman of the Board added: “I am confident that their leadership will have a highly meaningful impact on Vuja De’s ability to translate our core anti-metastasis drug discovery platform to ground-breaking therapies against cancer progression and to our success in building a strong and leading company in the fight against cancer.”

Vuja De has been collaborating with Dr. Chand Khanna, Chief Science Officer of Ethos Veterinary Health and President of Ethos Discovery. Through this interaction VuJa De and Ethos have an innovative collaborative plan and path for metastasis-focused drug development that includes clinical trials in pet dogs with cancer (i.e. comparative oncology).

“I am delighted to join the leadership at Vuja De. Targeting metastatic progression has been my passion for over 20 years and the team at Vuja De stands poised to rapidly translate new findings from its metastasis drug screens to effective drugs for the primary unmet need for cancer patients,” said Dr. Khanna.

Dr. Lee Helman stated:“I am delighted to join the Vuja De board and to work with the team to do whatever is needed to help bring treatments that prevent cancer progression and recurrence to patients with osteosarcoma and other cancers.”

“Ethos Veterinary Health is excited and highly supportive of the planned collaboration with Vuja De, beginning with Dr. Khanna joining the leadership team and soon leading to comparative oncology clinical trials that will develop effective treatments for both human and canine cancer patients,” said Ames Prentiss, CEO of Ethos Veterinary Health.

Dr. Chand Khanna

Dr. Khanna was the longtime Head of the NCI Pediatric Oncology Branch’s Tumor and Metastasis Biology Section, and the Founding Director of the Center for Cancer Research, Comparative Oncology Program. His research interests and responsibilities focused on the problem of cancer metastasis and the discovery of new options to treat patients with metastasis. Dr. Khanna has over 100 publications in the area of cancer biology and therapy. He is currently the Chief Science Officer of Ethos Veterinary Health and President of the non-profit incubator of scientific innovation, Ethos Discovery (501c.3.). In these roles Dr. Khanna seeks to improve outcomes for human and pet patients with complex medical problems through the development of novel therapeutics and diagnostics.

Dr. Lee Helman

Dr. Helman is Section Head of Basic and Translational Research within the Children’s Center for Cancer and Blood Diseases and Director of the Cancer and Blood Diseases Research Program of the Saban Research Institute of Children’s Hospital Los Angeles. He is also Professor of Pediatrics in the Keck School of Medicine of USC. Dr. Helman has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. He has also trained many investigators in the field of pediatric sarcomas. One current area of active research at Children’s Hospital Los Angeles focuses on using full genomic classification of osteosarcoma tumors to improve therapy, as well as testing novel therapeutic drugs and drug combinations in patients with osteosarcoma. Dr. Helman received his medical degree from the University of Maryland School of Medicine magna cum laude in 1980 and was elected to Alpha Omega Alpha. He has served as scientific director for clinical research in the Center for Cancer Research at the NIH until 2016. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He is a past member of the Board of Governors of the Clinical Center at NIH. In addition to his many appointments with different organization, he has been appointed director of the Osteosarcoma Institute.


About Comparative Oncology

In the setting of cancer drug development, comparative oncology involves the inclusion of dogs with naturally occurring cancer in clinical trials, where novel or repurposed drugs are tested to answer questions that cannot be answered in conventional animal models of cancer or human clinical trials.

About Osteosarcoma

Osteosarcoma is an aggressive cancer of the bone in dogs and human patients and is the most common type of bone cancer in children and teens. Despite successful control of the primary tumor and follow-up chemotherapy, metastasis continues to be the most common cause of mortality for both species. The last 30 years have brought little improvement in survival outcomes for children with osteosarcoma, despite intensification of therapy. Due to lack of improved outcomes, new approaches to therapy are highly needed. Furthermore, if targeted therapeutics are found to prevent metastasis in this human cancer, a strong biological rationale would exist for the evaluation of such a therapy in other human cancers.

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning, growth for team members, and the development of collaborative relationships. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)3 non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org

About Vuja De Sciences

Vuja De is a biotechnology startup dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our initial focus is osteosarcoma. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs. For more information, please visit vujade-life.com.

Ethos Discovery Receives Support from Citizens Bank

,

Woburn, Mass. — November 1, 2019: Ethos Discovery is excited to announce a $5,000 grant received by Citizens Bank in support of the Ethos Discovery Research program. This contribution will help Ethos Discovery continue its work to improve health outcomes for humans and animals with complex medical problems.

Ethos Discovery is a 501(c)(3) nonprofit that internally develops and answers its own clinical research questions. We are agnostic to the source of good ideas and uniquely positioned, with the support of Ethos Veterinary Health, to reach patients and doctors nationally and partner with key leaders in their field internationally. Ethos Discovery pursues impactful research that will make a difference where it is most important, at the point of care and to patients and families in the community and beyond. Our work is funded through philanthropic donations from like-minded individuals and organizations like Citizens Bank.

“Citizens Bank is a strong supporter of the community and we are grateful for their generous donation toward our important work.” said Chand Khanna, DVM, PhD, DACVIM (Onc), President of Ethos Discovery, and Chief Science Officer of Ethos Veterinary Health.

# # #


About Ethos Discovery

Ethos Discovery is a 501(c)3 non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org

About Citizens Financial Group, Inc.

Citizens Financial Group, Inc. is one of the nation’s oldest and largest financial institutions, with $164.4 billion in assets as of September 30, 2019. Headquartered in Providence, Rhode Island, Citizens offers a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. Citizens helps its customers reach their potential by listening to them and by understanding their needs in order to offer tailored advice, ideas and solutions. In Consumer Banking, Citizens provides an integrated experience that includes mobile and online banking, a 24/7 customer contact center and the convenience of approximately 2,900 ATMs and approximately 1,100 branches in 11 states in the New England, Mid-Atlantic and Midwest regions. Consumer Banking products and services include a full range of banking, lending, savings, wealth management and small business offerings. In Commercial Banking, Citizens offers corporate, institutional and not-for-profit clients a full range of wholesale banking products and services, including lending and deposits, capital markets, treasury services, foreign exchange and interest rate products, and asset finance. More information is available at www.citizensbank.com or visit us on Twitter, LinkedIn or Facebook.

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning, growth for team members, and the development of collaborative relationships. For more information, visit ethosvet.com.

LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital

,

Source: LexaGene Holdings Inc

BEVERLY, Mass., June 05, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGFTSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health.

“This placement marks a very significant milestone for the Company and for the diagnostics industry.  We have generated a long list of interested users who want to test our technology.  From this list, we selected Mass Vet to be our first site due to their reputation for being pioneers and thought leaders in veterinary medicine.  The doctors at Mass Vet are eager to test our cutting-edge technology to provide the best possible treatment for their patients,” said Dr. Jack Regan, CEO and Founder of LexaGene. “Following the placement at Mass Vet, we will continue placing our devices at various other sites throughout the United States as part of our ongoing beta test program. This will enable potential customers to experience the technology in their own facility so that they can compare LX-generated results to their standard testing methods. We are confident these users will quickly appreciate the benefits of our technology and this will help seed future sales.”

The beta LX prototype is expected to identify the presence of bacteria in the overwhelming majority of urinary tract infections.  In addition, the beta prototype will simultaneously screen samples for common antibiotic resistance factors providing veterinarians the information they need to select the best treatment for their patients.

“Emergency and critical care veterinarians are eagerly awaiting the commercialization of an accurate instrument that can identify the cause of an infection and whether any antibiotic resistance factors are detected.  We are very excited to have the opportunity to first test LexaGene’s technology.  It is amazing that their instrument returns results so quickly, as we are used to waiting 3 days to get results back.  Shortening the turn-around time for quality results will lead to much better patient care,” said Dr. Chand Khanna DVM, PhD, DACVIM (Onc), DACVP (Hon), Chief Science Officer of Ethos Veterinary Health and President of Ethos Discovery.

A video interview with Dr. Jack Regan regarding this news can be viewed here.

We are pleased to announce that LexaGene will host a webinar tomorrow, Thursday, June 6th at 11 AM EST to provide an overview of the Company.  The webinar signup can be accessed at this link.

To be added to the LexaGene email distribution list, please subscribe on the Company website.

 


About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

About Ethos Veterinary Health
Ethos Veterinary Health is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, ethosvet.com.

Media Contacts
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206
nridgedale@lexagene.com

Investor Relations
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
jadelaar@lexagene.com

TGEN-Ethos Study Underscores Need for Setting High Standards in Veterinary Cancer Diagnostics

, , , ,

Written by Steve Yozwiak

PHOENIX, Ariz. — May 21, 2019 — Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, announced today that they have developed a highly accurate test for the diagnosis of canine lymphoma.

In a study published in the Journal of Veterinary Internal Medicine (JVIM), Ethos and TGen found that their test, called ePARR, was more than 90 percent accurate among a range of lymphoma sample types (link to the complete JVIM article is below).

TGen conducted genetic analysis of more than 180 dogs with naturally occurring cancer to confirm if they had lymphoma, and then determine exactly what type of lymphoma, which is a common and aggressive cancer in dogs.

“An ongoing need exists for robust validation of molecular diagnostics in veterinary medicine. This study is an example of exhaustive validation of one such molecular test,” said Dr. Will Hendricks, an Assistant Professor in TGen’s Integrated Cancer Genomics Division, and one of the study’s co-senior authors. “Overall, ePARR is more than 90 percent accurate across sample types and diagnostic settings.”

The study authors suggest that such tests could be even more accurate if testing facilities adopted more uniform testing techniques, established uniform high performance standards, and made their results more readily available to the general research community.

“In the veterinary diagnostic area, there is a need for methodological consistency and transparency. Each lab has their own methods for how to run the same test,” said Dr. Chand Khanna, Chief Science Officer of Ethos Veterinary Health, and also a co-senior author of the study. “Our validation of ePARR included over 180 dogs and a broad diversity of sample types, including cell pellets, air dried aspirates, and formalin-fixed paraffin-embedded tissues.”

Shukmei Wong, who is a TGen Senior Research Associate in the Hendricks Laboratory, who conducted the study experiments, and is a co-author of the study, said: “I hope this paper will inspire more reporting of assay methods and metrics, and help drive the creation of reference standards and more consistent protocols in diagnostics in veterinary medicine.”

Dr. Sam Stewart, Science Commercialization Fellow at Ethos Veterinary Health, agrees:

“It is truly unique to see such complete rigorous validation of a molecular assay in this field, and we hope this standard of transparency and quality will be followed by others. As a Critical Care doctor, I am proud to offer this high level of quality in a diagnostic assay to my patients.”

Molecular level investigations into dog DNA could someday not only improve the health of dogs with cancer, but also help contribute to a better understanding of cancer in humans, as well.

This study was funded by non-profit Ethos Discovery, which is evaluating options to make the ePARR test available to veterinarians and pet owners.

The study — Polymerase Chain Reaction for Antigen Receptor Rearrangement (PARR): Benchmarking performance of a lymphoid clonality assay in diverse canine sample types — was published April 2 in the Journal of Veterinary Internal Medicine.

No dogs were harmed during this research. Only tissue samples from pet dogs with naturally occurring cancers were examined.

 

Related Links:

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning, growth for team members, and the development of collaborative relationships. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)(3) non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org.

About TGen, an affiliate of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process.

For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen

Media Contact at TGen:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org

Nationwide, Multi-center, Prospective Study of Canine Splenic Hemangiosarcoma Complete

,

Cutting Edge Cancer Research in Veterinary Specialty Practice: Ethos Veterinary Health Completes First-Ever, Nationwide, Multicenter, Prospective Study of Canine Splenic Hemangiosarcoma

Woburn, Mass. — Jan. 15, 2019 — Ethos Veterinary Health(Ethos) has completed the patient accrual phase of their new Canine Hemangiosarcoma Molecular Profiling (CHAMP) study.

Hemangiosarcoma is one of the most malignant forms of cancer in dogs and CHAMP is the first nationwide, multicenter, prospective study of canine splenic hemangiosarcoma, which is a cancer of the blood vessels often affecting the spleen.

“Ethos is proud of this unprecedented milestone and of our investments in innovation that will improve outcomes for our patients,” said Ames Prentiss, CEO of Ethos Veterinary Health.

The clinical description of this population of dogs with splenic tumor rupture, a common diagnosis made on an emergency basis, is expected to be submitted for publication before the end of Q1 2019 by Dr. Sam Stewart, DACVECC and colleagues at Ethos.

“I expect the CHAMP study to change many misperceptions of hemangiosarcoma in the veterinary community, and ultimately help pet owners and veterinarians make better decisions regarding treatment,” said Sam Stewart, DVM, DACVECC, Science Commercialization Fellow at Ethos Veterinary Health.

The study also provided state-of-the-art care to dogs with splenic tumor rupture over a 12-month period and allowed for the collection samples for molecular analysis. CHAMP will result in a molecular characterization of genomic alterations in canine hemangiosarcoma which will help identify dogs with distinct prognoses and potentially life-saving molecularly-targeted therapies. Publication of these genomic data is expected in Q2 2019.

“When viewed from the perspective of a veterinarian trained to treat cancer – I am a veterinary Oncologist – the new genomic analysis of this highly aggressive cancer has already provided an opportunity for me to treat dogs differently,” said Chand Khanna, DVM, PhD, DACVIM (Onc), Chief Science Officer of Ethos Discovery. “We are very excited to now launch clinical trials that will assess these new treatments and change outcomes for dogs with this very aggressive cancer.”

A critical component of this prospective study will be the molecular characterization of the disease recently completed through a collaboration of Ethos and The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This Ethos-TGen collaboration allowed for the use of advanced next generation sequencing technology of tumor and blood samples collected from the CHAMP dogs.

Will Hendricks, Ph.D., Assistant Professor, Integrated Cancer Genomics Division of TGen, added: “The results of this collaboration between TGen and Ethos will bring needed evidence to the field of molecular and precision medicine. We are not only excited about the application of these data to dogs, but also to human patients with very similar cancers as part of a comparative approach to cancer biology and therapy, so-called comparative oncology.”

These new trials will open through Ethos practices in Q2 2019. In parallel, additional studies are ongoing to develop a molecular diagnostic to help define the prognosis of individual dogs and identify optimal molecularly derived treatments for each patient.

 

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)(3) non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org.

About TGen, an affiliate of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is affiliated with City of Hope, a world-renowned independent research and cancer and diabetes treatment center: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Development Collaboration to Prevent Cancer Recurrence

,

First-Ever Human Health and Animal Health Drug Development Collaboration to Prevent Cancer Recurrence

Ethos Veterinary Health and Vuja De Sciences to utilize novel cellular assays of cancer metastasis and integration of pet dogs with cancer to empower innovative metastasis-focused drug development collaboration.

Ethos Veterinary Health (“Ethos”) and Vuja De Sciences (“Vuja De”) have entered into a Memorandum of Understanding to identify and develop new cancer therapeutics that are uniquely suited to prevent cancer metastasis and recurrence.

“This is the first-ever comprehensive drug development strategy to align cancer’s major unmet therapeutic need (i.e. preventing cancer recurrence or metastasis) with a scientific drug discovery and development pipeline that targets the biology of cancer metastasis. We are targeting the cancer cells that escape and cause recurrence at distant sites,” explained David Warshawsky, Ph.D., Founder and CEO of Vuja De. He added: “We will begin with osteosarcoma, a tumor with high unmet need in both humans and pet dogs. Since osteosarcoma shares cancer related biology with other cancers, we believe that drugs that are effective in osteosarcoma may also be effective for other pediatric/adolescent cancers, as well as adult cancers such as kidney cancer, melanoma and breast cancer, depending on the mechanisms of action of the identified drugs.”

Robert Hurst, Ph.D., Co-founder and Chief Scientific Officer of Vuja De said: “The drug discovery strategy is built around novel cellular assays of cancer metastasis rather than the traditional drug screening process that simply assesses growth of dividing cancer cells”.

… [Read More]

 

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced specialty medical care for pets. Our approach includes a focus on transformative science, continuous learning, growth opportunities for team members, and collaboration. For more information, please visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)(3) non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org.

About Vuja De Sciences

Vuja De is a biotechnology startup dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our initial focus is osteosarcoma. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs. For more information, please visit vujade-life.com.

ACI and Ethos Veterinary Health Form New Clinical Trial Network

,

New Opportunity for Rapid Approval of Innovative Therapies for the Animal Health Market

WOBURN, Mass. (March 8, 2017) — Animal Clinical Investigation (ACI) and Ethos Veterinary Health (Ethos) have formed a strategic alliance offering a new mechanism to deliver market approval of pharmaceuticals and therapeutics in Animal Health. This relationship offers a unique opportunity for collaboration with organizations in the pharmaceutical industry, diagnostic developers and medical device companies.

The two companies are establishing a multi-specialty clinical trial network comprised of a geographically diverse, nationwide collection of Ethos veterinary hospitals. They are selected based on their interest and experience in clinical research, and their depth and strength in the veterinary specialties of internal medicine, dermatology, oncology, emergency and critical care medicine, diagnostic imaging and surgery.

“This is an exciting partnership for Ethos. It will ensure that we are on the forefront of medical discoveries through the participation of our motivated doctors trained in the rigor of conducting clinical trials by ACI, a leading group in veterinary medicine that oversees trial delivery.”

Keith Richter, DVM, MSEL, DACVIM
Chief Medical Officer

ACI, focused on complex medical problems in animals and the design and execution of clinical trials, has been a leader in bringing clinical trials into the private practice setting. Adding the Ethos multi-specialty trial network to ACI’s previously assembled group expands its reach beyond oncology and dermatology.

“Speaking on the new ACI-Ethos clinical trial network, Kristen Khanna, PhD, MBA, stated that, “We look forward to continuing to expand ACI’s role in clinical trial conduct in specialty medicine by joining with Ethos investigators and their staff.  Ethos already practices medicine at the highest level – this opportunity allows Ethos and ACI to share our science-driven mindset with study sponsors and pet owners.”

Kristen Khanna, PhD, MBA
ACI Chief Executive Officer

The opportunity for rapid and successful approval of innovative therapies is a key benefit to study sponsors, based on the following:

  • Rapid accrual of data, resulting in faster studies, is enabled by the substantial caseload offered by the Ethos network and the optimized trial participation through ACI’s management
  • Highly motivated and experienced clinicians and medical monitoring ensure quality data
  • Ethos’ strategic focus on scientific innovation

Clinical studies in the areas of orthopedics, pain management, gastrointestinal disorders, immune mediated disease, oncology and the management of sepsis in dogs are currently being planned and will be among the first to be launched by the new ACI-Ethos multi-specialty network.

Ethos Diagnostic Science Conducts Accuracy Testing for Samsung

, ,

Ethos Diagnostic Science was recently contracted by Samsung to study the accuracy of the new PT10V blood analyzer as Samsung prepared to enter the US Animal Health market. The small, point-of-care chemistry analyzer had been evaluated by Samsung in Korea prior to then, but it had not been studied against any reference standards.

Using industry recommendations for the validation of new laboratory assays methods, Ethos Diagnostic Science compared all instruments by testing several hundred canine, feline and equine blood specimens covering a wide range of values. Standard statistical methods for evaluating correlation – comparing the accuracy of the new analyzer with results obtained, on the same samples, from the reference analyzers – were utilized. The results showed excellent and acceptable data for all of the dog and cat samples, and nearly all of the horse specimens.

Dr. Andrew Loar, Vice President of Laboratories for Ethos Veterinary Health, said, “Of the hundreds of samples evaluated during the study, no operative or functional errors occurred, showing consistent and reliable results.” The findings were also useful for establishing the analyzer’s reference intervals (normal ranges) for all three species.

This was part of a collaborative effort between Samsung and Henry Schein.  … Read this article